Location Cherry Hill, New Jersey, United States Regions Greater Philadelphia Area, East Coast, Northeastern US Gender Female
Jacqueline H. Barnea is the President, CEO and co-founder of BioIncept, LLC, a clinical stage biotechnology and intellectual property portfolio holding company that develops and manages the translation of the PreImplantation Factor (PIF) platform towards its intended clinical potential. Dr. Barnea brings her global vision, adaptability,
, flexibility and out-of-the-box thinking to this transformational technology project. She creates, adapts, and brings consensus to the scientific, legal and patent management of the PreImplantation Factor (PIF), the paradigm-shifting technology that is PIF.
Having earned her Doctorate summa cum laude in International Business Law in 1976 from the Sorbonne-Pantheon University in Paris, Dr. Barnea taught graduate-level students and corporate executive courses in decision-making, comparative management, international negotiations and marketing, while preparing for a corporate law and academic career. She redirected her career towards biotechnology upon co-founding BioIncept.
Dr. Barnea brings nearly two decades of uniquely adapted biotech building experience to BioIncept’s vast transformational platform. This journey began with global collaborations with leading scientists at prominent institutions, who then independently produced their own data and validated PIF scientific results. She has guided the PIF project from its inception to clinical reality, forging an innovative path for PIF by carefully monitoring pharmaceutical transition and adaptive reality. Dr. Barnea has surrounded herself with expert advisors and respected legal and patent teams to help her guide the Company successfully through uncharted territory.
Her next step at BioIncept is to safely shepherd PIF through FDA-approved, University-sponsored Phase I/II clinical trials, both therapeutic and diagnostic. At the completion of those trials, Dr. Barnea and her team will position BioIncept to leverage the appropriate industry partnerships to ensure that PIF reaches its full potential and that BioIncept provides therapeutic and diagnostic products to address a vast array of unmet global needs.
